Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dabigatran, which is administered in a fixed dose and does not require laboratory monitoring, may be suitable for extended treatment of venous thromboembolism. METHODS: In two double-blind, randomized trials, we compared dabigatran at a dose of 150 mg twice daily with warfarin (active-control study) or with placebo (placebo-control study) in patients with venous thromboembolism who had completed at least 3 initial months of therapy. RESULTS: In the active-control study, recurrent venous thromboembolism occurred in 26 of 1430 patients in the dabigatran group (1.8%) and 18 of 1426 patients in the warfarin group (1.3%) (hazard ratio with dabigatran, 1.44; 95% confidence interval [CI], 0.78 to 2.64; P=0.01 for noninferiority). Major bleeding occurred in 13 patients in the dabigatran group (0.9%) and 25 patients in the warfarin group (1.8%) (hazard ratio, 0.52; 95% CI, 0.27 to 1.02). Major or clinically relevant bleeding was less frequent with dabigatran (hazard ratio, 0.54; 95% CI, 0.41 to 0.71). Acute coronary syndromes occurred in 13 patients in the dabigatran group (0.9%) and 3 patients in the warfarin group (0.2%) (P=0.02). In the placebo-control study, recurrent venous thromboembolism occurred in 3 of 681 patients in the dabigatran group (0.4%) and 37 of 662 patients in the placebo group (5.6%) (hazard ratio, 0.08; 95% CI, 0.02 to 0.25; P<0.001). Major bleeding occurred in 2 patients in the dabigatran group (0.3%) and 0 patients in the placebo group. Major or clinically relevant bleeding occurred in 36 patients in the dabigatran group (5.3%) and 12 patients in the placebo group (1.8%) (hazard ratio, 2.92; 95% CI, 1.52 to 5.60). Acute coronary syndromes occurred in 1 patient each in the dabigatran and placebo groups. CONCLUSIONS: Dabigatran was effective in the extended treatment of venous thromboembolism and carried a lower risk of major or clinically relevant bleeding than warfarin but a higher risk than placebo. (Funded by Boehringer Ingelheim; RE-MEDY and RE-SONATE ClinicalTrials.gov numbers, NCT00329238 and NCT00558259, respectively.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For patients who are treated with dabigatran for secondary prevention, only the standard regimen of 150 mg twice daily has been studied. 310”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [310]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Three DOACs have been studied for secondary prevention of recurrent VTE after completion of the primary treatment phase. 306,310,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [310]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Self-citationAntithrombotic Therapy for Venous Thromboembolic Disease
Hyers, T. M., Agnelli, G., Hull, R. D., Morris, T. A., Samama, M., Tapson, V., & Weg, J. G. (2001) · Chest · doi:10.1378/chest.119.1_suppl.176s · Cited by 2,042
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Self-citationKearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M. J., Anderson, D. R., Turpie, A. G., Green, D., Ginsberg, J. S., Wells, P., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,072
Self-citation(2003) · New England Journal of Medicine · doi:10.1056/nejmoa035451 · Cited by 887
Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808
Self-citationKearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035422 · Cited by 751
Self-citationNewly identified events in the RE-LY trial
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Reilly, P. A., & Wallentin, L. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1007378 · Cited by 688
Research works printed but not linked: 1
- Hutten BA, 2000, Cochrane Database Syst Rev, 3, CD001367
Cited by
Konstantinides, S. V., Meyer, G., Becattini, C., Bueno, H., Geersing, G.-J., Harjola, V.-P., Huisman, M. V., Humbert, M., Jennings, C. S., Jiménez, D., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz405 · Cited by 4,916
Self-citationAntithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
“ashx?url=/data/ (Table 7, e-Table 9).(47) Extended treatment with dabigatran,(47) rivaroxaban,(21) and apixaban(48) markedly reduces recurrent VTE without being associated with much bleeding (Tables 8-10, e-Tables 10-12).”
BackgroundSelf-citation2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism
Authors/Task Force Members, Konstantinides, S. V., Torbicki, A., Agnelli, G., Danchin, N., Fitzmaurice, D., Galiè, N., Gibbs, J. S. R., Huisman, M. V., Humbert, M., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu283 · Cited by 3,128
Steffel, J., Verhamme, P., Potpara, T. S., Albaladejo, P., Antz, M., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy136 · Cited by 2,123
Konstantinides, S. V., Meyer, G., Becattini, C., Bueno, H., Geersing, G.-J., Harjola, V.-P., Huisman, M. V., Humbert, M., Jennings, C. S., Jiménez, D., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01647-2019 · Cited by 1,619
“Dabigatran was compared with warfarin or placebo in two different studies (Supplementary Data Table 15).(350) In these studies, dabigatran was non-inferior to warfarin for the prevention of confirmed recurrent symptomatic VTE or VTE-related death, and more effective than placebo for the prevention of symptomatic recur…”
BackgroundMethodOrtel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001830 · Cited by 1,489
“Patients placed a high value on the benefits of risk reduction in VTE recurrence and PTS.(310) However, there is important variability in how individual patients may value the risk of thrombosis vs the risk of bleeding.”
BackgroundInfluentialSelf-citationKaatz, S., Ahmad, D., Spyropoulos, A. C., & Schulman, S. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13140 · Cited by 1,419
Self-citationSteffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., et al. (2021) · EP Europace · doi:10.1093/europace/euab065 · Cited by 1,132
Deep vein thrombosis and pulmonary embolism
Di Nisio, M., van Es, N., & Büller, H. R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30514-1 · Cited by 994
Antithrombotic Therapy for VTE Disease
Stevens, S. M., Woller, S. C., Kreuziger, L. B., Bounameaux, H., Doerschug, K., Geersing, G.-J., Huisman, M. V., Kearon, C., King, C. S., Knighton, A. J., et al. (2021) · Chest · doi:10.1016/j.chest.2021.07.055 · Cited by 1,043
Self-citationLyman, G. H., Carrier, M., Ay, C., Di Nisio, M., Hicks, L. K., Khorana, A. A., Leavitt, A. D., Lee, A. Y. Y., Macbeth, F., Morgan, R. L., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003442 · Cited by 893
Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis
Schulman, S., Kakkar, A. K., Goldhaber, S. Z., Schellong, S., Eriksson, H., Mismetti, P., Christiansen, A. V., Friedman, J., Le Maulf, F., Peter, N., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.004450 · Cited by 923
Self-citationKakkos, S. K., Gohel, M., Baekgaard, N., Bauersachs, R., Bellmunt-Montoya, S., Black, S. A., ten Cate-Hoek, A. J., Elalamy, I., Enzmann, F. K., Geroulakos, G., et al. (2021) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2020.09.023 · Cited by 743
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
Weitz, J. I., Lensing, A. W. A., Prins, M. H., Bauersachs, R., Beyer-Westendorf, J., Bounameaux, H., Brighton, T. A., Cohen, A. T., Davidson, B. L., Decousus, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700518 · Cited by 787
Self-citationFrontera, J. A., Lewin III, J. J., Rabinstein, A. A., Aisiku, I. P., Alexandrov, A. W., Cook, A. M., del Zoppo, G. J., Kumar, M. A., Peerschke, E. I. B., Stiefel, M. F., et al. (2016) · Neurocritical Care · doi:10.1007/s12028-015-0222-x · Cited by 706
“Direct thrombin inhibitors (DTI) are used for primary stroke prevention in patients with non-valvular atrial fibrillation [152], for treatment of deep venous thrombosis and pulmonary embolus [153, 154], and in the management of heparin-induced thrombocytopenia [155].”
BackgroundPrins, M. H., Lensing, A. W., Bauersachs, R., van Bellen, B., Bounameaux, H., Brighton, T. A., Cohen, A. T., Davidson, B. L., Decousus, H., Raskob, G. E., et al. (2013) · Thrombosis Journal · doi:10.1186/1477-9560-11-21 · Cited by 551
“Several direct oral anticoagulants have been evaluated recently for the acute and extended treatment of symptomatic VTE [5-10], and their use could obviate the need for parenteral treatment and laboratory monitoring of the anticoagulant effect.”
van der Hulle, T., Kooiman, J., den Exter, P. L., Dekkers, O. M., Klok, F. A., & Huisman, M. V. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12485 · Cited by 536
Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Akl, E. A., Kahale, L. A., Barba, M., Neumann, I., Labedi, N., Terrenato, I., Sperati, F., Muti, P., & Schünemann, H. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006650.pub4 · Cited by 428
Wolberg, A. S., Rosendaal, F. R., Weitz, J. I., Jaffer, I. H., Agnelli, G., Baglin, T., & Mackman, N. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.6 · Cited by 369
Mazzolai, L., Aboyans, V., Ageno, W., Agnelli, G., Alatri, A., Bauersachs, R., Brekelmans, M. P. A., Büller, H. R., Elias, A., Farge, D., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx003 · Cited by 402
Management of venous thrombo-embolism: an update
Konstantinides, S., & Torbicki, A. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu243 · Cited by 383
“In RE-SONATE, 1353 patients were randomized to dabigatran or placebo for an additional anticoagulation period of 6 months.(76) Dabigatran was associated with a 92% relative risk reduction in symptomatic recurrent VTE.”
BackgroundInfluentialVenous Thromboembolism: Advances in Diagnosis and Treatment
Tritschler, T., Kraaijpoel, N., Le Gal, G., & Wells, P. S. (2018) · JAMA · doi:10.1001/jama.2018.14346 · Cited by 357
Huisman, M. V., Barco, S., Cannegieter, S. C., Le Gal, G., Konstantinides, S. V., Reitsma, P. H., Rodger, M., Noordegraaf, A. V., & Klok, F. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.28 · Cited by 336
Guidance for the treatment of deep vein thrombosis and pulmonary embolism
Streiff, M. B., Agnelli, G., Connors, J. M., Crowther, M., Eichinger, S., Lopes, R., McBane, R. D., Moll, S., & Ansell, J. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1317-0 · Cited by 344
“Acute coronary syndrome occurred in 1 patient in both groups [111].”
BackgroundAcute Pulmonary Embolism: A Review
Freund, Y., Cohen-Aubart, F., & Bloom, B. (2022) · JAMA · doi:10.1001/jama.2022.16815 · Cited by 301
Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment
Burnett, A. E., Mahan, C. E., Vazquez, S. R., Oertel, L. B., Garcia, D. A., & Ansell, J. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1310-7 · Cited by 333
Management of Pulmonary Embolism
Konstantinides, S. V., Barco, S., Lankeit, M., & Meyer, G. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.11.061 · Cited by 330
Chai-Adisaksopha, C., Crowther, M., Isayama, T., & Lim, W. (2014) · Blood · doi:10.1182/blood-2014-07-590323 · Cited by 326
Khan, F., Rahman, A., Carrier, M., Kearon, C., Weitz, J. I., Schulman, S., Couturaud, F., Eichinger, S., Kyrle, P. A., Becattini, C., et al. (2019) · BMJ · doi:10.1136/bmj.l4363 · Cited by 328
Self-citationDuration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism
Kearon, C., & Akl, E. A. (2014) · Blood · doi:10.1182/blood-2013-12-512681 · Cited by 279
Self-citationManagement and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin
Majeed, A., Hwang, H.-G., Connolly, S. J., Eikelboom, J. W., Ezekowitz, M. D., Wallentin, L., Brueckmann, M., Fraessdorf, M., Yusuf, S., & Schulman, S. (2013) · Circulation · doi:10.1161/circulationaha.113.002332 · Cited by 277
“63 Creatinine, mol/L, median (range) 106 (44-968) 105 (43-800) 96 (17-577) Creatinine clearance, median (range) 52 (5-155) 55 (5-199) 62 (7-239) 0.”
Self-citationDirect Oral Anticoagulants in Patients With VTE and Cancer
Vedovati, M. C., Germini, F., Agnelli, G., & Becattini, C. (2015) · Chest · doi:10.1378/chest.14-0402 · Cited by 270
New Oral Anticoagulants in Elderly Adults: Evidence from a Meta‐Analysis of Randomized Trials
Sardar, P., Chatterjee, S., Chaudhari, S., & Lip, G. Y. H. (2014) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12799 · Cited by 267
“Another study for extended treatment of VTE did not report groupspecific data for the elderly population.(29) The basic baseline demographic characteristics of participants in the included trials are summarized in Table 1.”
BackgroundAspirin for the Prevention of Recurrent Venous Thromboembolism: The INSPIRE Collaboration
Simes, J., Becattini, C., Agnelli, G., Eikelboom, J. W., Kirby, A. C., Mister, R., Prandoni, P., & Brighton, T. A. (2014) · Circulation · doi:10.1161/circulationaha.114.008828 · Cited by 262
Couturaud, F., Sanchez, O., Pernod, G., Mismetti, P., Jego, P., Duhamel, E., Provost, K., dit Sollier, C. B., Presles, E., Castellant, P., et al. (2015) · JAMA · doi:10.1001/jama.2015.7046 · Cited by 249
Self-citationSharma, M., Cornelius, V. R., Patel, J. P., Davies, J. G., & Molokhia, M. (2015) · Circulation · doi:10.1161/circulationaha.114.013267 · Cited by 243
“194 Advanced age is a significant risk factor for atrial fibrillation (AF) and venous thromboembolism (VTE).(1,2) AF prevalence estimates are <0.”
BackgroundAgeno, W., Mantovani, L. G., Haas, S., Kreutz, R., Monje, D., Schneider, J., van Eickels, M., Gebel, M., Zell, E., & Turpie, A. G. G. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00257-4 · Cited by 243
Treatment of Venous Thromboembolism
Wells, P. S., Forgie, M. A., & Rodger, M. A. (2014) · JAMA · doi:10.1001/jama.2014.65 · Cited by 237
Sterne, J. A., Bodalia, P. N., Bryden, P. A., Davies, P. A., López-López, J. A., Okoli, G. N., Thom, H. H., Caldwell, D. M., Dias, S., Eaton, D., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21090 · Cited by 198
Direct oral anticoagulants: evidence and unresolved issues
Chan, N., Sobieraj-Teague, M., & Eikelboom, J. W. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32439-9 · Cited by 189
Chai‐Adisaksopha, C., Hillis, C., Isayama, T., Lim, W., Iorio, A., & Crowther, M. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13139 · Cited by 190
Overview of the New Oral Anticoagulants: Opportunities and Challenges
Yeh, C. H., Hogg, K., & Weitz, J. I. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.303397 · Cited by 189
Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes
Khairani, C. D., Bejjani, A., Piazza, G., Jimenez, D., Monreal, M., Chatterjee, S., Pengo, V., Woller, S. C., Cortes-Hernandez, J., Connors, J. M., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.10.008 · Cited by 172
Self-citationCastellucci, L. A., Cameron, C., Le Gal, G., Rodger, M. A., Coyle, D., Wells, P. S., Clifford, T., Gandara, E., Wells, G., & Carrier, M. (2013) · BMJ · doi:10.1136/bmj.f5133 · Cited by 193
Treatment of cancer-associated thrombosis
Lee, A. Y. Y., & Peterson, E. A. (2013) · Blood · doi:10.1182/blood-2013-04-460162 · Cited by 183
Almutairi, A. R., Zhou, L., Gellad, W. F., Lee, J. K., Slack, M. K., Martin, J. R., & Lo-Ciganic, W.-H. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.05.358 · Cited by 171
Halton, J., Brandão, L. R., Luciani, M., Bomgaars, L., Chalmers, E., Mitchell, L. G., Nurmeev, I., Sharathkumar, A., Svirin, P., Gorbatikov, K., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30368-9 · Cited by 168
Carrier, M., Khorana, A. A., Zwicker, J. I., Noble, S., & Lee, A. Y. Y. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12338 · Cited by 174
Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism
Witt, D. M., Clark, N. P., Kaatz, S., Schnurr, T., & Ansell, J. E. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1319-y · Cited by 161
“Little is known about the use of DOACs in patients with an estimated CrCl\ 30 mL/min, as these patients were excluded from clinical trials comparing DOACs to warfarin for VTE treatment [14–20].”
BackgroundSteffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Hæusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., et al. (2021) · EP Europace · doi:10.1093/europace/euab157 · Cited by 171
Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer
Kahale, L. A., Hakoum, M. B., Tsolakian, I. G., Alturki, F., Matar, C. F., Terrenato, I., Sperati, F., Barba, M., Yosuico, V. E. D., Schünemann, H. J., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006650.pub5 · Cited by 170
“Schulman 2013 (RE-MEDY) {published data only} Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.”
Background2014 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism
Konstantinides, S., Torbicki, A., Agnelli, G., Danchin, N., Fitzmaurice, D. A., Galiè, N., Gibbs, J. S. R., Huisman, M., Humbert, M. J. C., Kucher, N., et al. (2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2014.12.002 · Cited by 153
“01 for non-inferiority).(370) The rate of major bleeding was 0.”
InfluentialKhan, F. A., Tritschler, T., Kimpton, M., Wells, P. S., Kearon, C., Weitz, J. I., Buller, H. R., Raskob, G. E., Ageno, W., Couturaud, F., et al. (2021) · Annals of Internal Medicine · doi:10.7326/m21-1094 · Cited by 152
Self-citationReversal of anticoagulants: an overview of current developments
Thiele, T., Selleng, K., & Greinacher, A. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-11-0982 · Cited by 161
Targeting factor Xa and thrombin: impact on coagulation and beyond
Esmon, C. T. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-09-0730 · Cited by 149
Creager, M. A., Barnes, G. D., Giri, J., Mukherjee, D., Jones, W. S., Burnett, A. E., Carman, T., Casanegra, A. I., Castellucci, L. A., Clark, S. M., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001415 · Cited by 254
Miller, C., Dorreen, A. P., Martel, M., Huynh, T. T., & Barkun, A. N. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.04.031 · Cited by 149
“Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation.”
InfluentialKakkos, S. K., Kirkilesis, G. I., & Tsolakis, I. A. (2014) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2014.05.001 · Cited by 138
Creager, M. A., Barnes, G. D., Giri, J., Mukherjee, D., Jones, W. S., Burnett, A. E., Carman, T., Casanegra, A. I., Castellucci, L. A., Clark, S. M., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.11.005 · Cited by 144
Ballestri, S., Romagnoli, E., Arioli, D., Coluccio, V., Marrazzo, A., Athanasiou, A., Girolamo, M. D., Cappi, C., Marietta, M., & Capitelli, M. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02333-9 · Cited by 146
“Dabigatran was as effective as warfarin in the extended treatment of VTE, exhibiting a lower risk of MB/CRNMB compared to warfarin but a higher risk compared to placebo [35].”
BackgroundDiagnosis and management of pulmonary embolism
Lapner, S. T., & Kearon, C. (2013) · BMJ · doi:10.1136/bmj.f757 · Cited by 144
Self-citationLutz, J., Jurk, K., & Schinzel, H. (2017) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s105771 · Cited by 143
Andreozzi, G. M., Bignamini, A. A., Davì, G., Palareti, G., Matuška, J., Holý, M., Pawlaczyk-Gabriel, K., Džupina, A., Юрьевич, С. Г., Didenko, Y. P., et al. (2015) · Circulation · doi:10.1161/circulationaha.115.016930 · Cited by 138
“2%, respectively).(10,13,14) Our study, however, has some limitations.”
Elsebaie, M. A., van Es, N., Langston, A. A., Buller, H. R., & Gaddh, M. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14398 · Cited by 142
Evolving use of new oral anticoagulants for treatment of venous thromboembolism
Yeh, C. H., Gross, P. L., & Weitz, J. I. (2014) · Blood · doi:10.1182/blood-2014-03-563056 · Cited by 137
Akl, E. A., Gunukula, S., Barba, M., Yosuico, V. E. D., van Doormaal, F. F., Kuipers, S., Middeldorp, S., Dickinson, H. O., Bryant, A., & Schünemann, H. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006652.pub3 · Cited by 118
Couturaud, F., Schmidt, J., Sanchez, O., Ballerie, A., Sevestre, M., Meneveau, N. F., Bertoletti, L., Connault, J., Benhamou, Y., Constans, J., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02842-3 · Cited by 118
Self-citationPrevention, Diagnostics and Treatment of Deep Vein Thrombosis. Russian Experts Consensus
Seliverstov, E. I., Lobastov, K. V., Ilyukhin, Е. А., Apkhanova, T. V., Akhmetzyanov, R. V., Akhtyamov, I. F., Barinov, V., Bakhmetiev, A. S., Belov, M. V., Александрович, Б. С., et al. (2023) · Journal of Venous Disorders · doi:10.17116/flebo202317031152 · Cited by 121
Klok, F. A., Kooiman, J., Huisman, M. V., Konstantinides, S., & Lankeit, M. (2014) · European Respiratory Journal · doi:10.1183/09031936.00040714 · Cited by 117
Portal vein thrombosis in cirrhosis: Controversies and latest developments
Harding, D., Perera, M. T. P. R., Chen, F. E., Olliff, S. P., & Tripathi, D. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i22.6769 · Cited by 119
Evolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants
Chan, N., Eikelboom, J. W., & Weitz, J. I. (2016) · Circulation Research · doi:10.1161/circresaha.116.306925 · Cited by 125
Long-term treatment of venous thromboembolism
Kearon, C., & Kahn, S. R. (2020) · Blood · doi:10.1182/blood.2019002364 · Cited by 127
Self-citationLevy, J. H., Spyropoulos, A. C., Samama, C. M., & Douketis, J. D. (2014) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2014.06.014 · Cited by 119
“Dabigatran was noninferior to warfarin (RE-MEDY [Secondary Prevention of Venous Thrombo Embolism (VTE)]) and superior to placebo (RE-SONATE [Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE]) for the prevention of recurrent VTE (40).”
MethodComparisons between Novel Oral Anticoagulants and Vitamin K Antagonists in Patients with CKD
Harel, Z., Sholzberg, M., Shah, P. S., Pavenski, K., Harel, S., Wald, R., Bell, C. M., & Perl, J. M. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013040361 · Cited by 108
Caldeira, D., Barra, M., Santos, A. T., Abreu, D., Pinto, F. J., Ferreira, J. J., & Costa, J. N. (2014) · Heart · doi:10.1136/heartjnl-2013-305288 · Cited by 112
Douxfils, J., Buckinx, F., Mullier, F., Minet, V., Rabenda, V., Reginster, J., Hainaut, P., Bruyère, O., & Dogné, J. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000515 · Cited by 108
Parenteral anticoagulation in ambulatory patients with cancer
Akl, E. A., Kahale, L. A., Hakoum, M. B., Matar, C. F., Sperati, F., Barba, M., Yosuico, V. E., Terrenato, I., Synnot, A., & Schünemann, H. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006652.pub5 · Cited by 102
Gu, Z., Wei, A., Zhang, C., Wang, X., Zhang, L., Shen, L., Li, Z., Pan, M.-M., Liu, X.-Y., Pu, J., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.05.056 · Cited by 111
Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children
Brandão, L. R., Albisetti, M., Halton, J., Bomgaars, L. R., Chalmers, E. A., Mitchell, L. G., Nurmeev, I. N., Svirin, P., Kuhn, T., Zapletal, O., et al. (2019) · Blood · doi:10.1182/blood.2019000998 · Cited by 105
The evolution of anticoagulant therapy.
Franchini, M., Liumbruno, G. M., Bonfanti, C., & Lippi, G. (2016) · PubMed · doi:10.2450/2015.0096-15 · Cited by 127
Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis
Caldeira, D., Barra, M., Pinto, F. J., Ferreira, J. J., & Costa, J. N. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7462-0 · Cited by 103
“NOACs were compared against placebo in one extended study period of an apixaban RCT in patients with post-VTE [24], and in two RCTs with ACS patients [20, 34].”
BackgroundInfluentialBleeding and antidotes in new oral anticoagulants
Majeed, A., & Schulman, S. (2013) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2013.07.001 · Cited by 99
Self-citationAdvantages and limitations of the new anticoagulants
Schulman, S. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12138 · Cited by 98
Self-citationEdoxaban: An Update on the New Oral Direct Factor Xa Inhibitor
Bounameaux, H., & Camm, A. J. (2014) · Drugs · doi:10.1007/s40265-014-0261-1 · Cited by 105
Eichinger, S., Heinze, G., & Kyrle, P. A. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000467 · Cited by 99
Direct‐acting oral anticoagulants: pharmacology, indications, management, and future perspectives
Gómez‐Outes, A., Suárez‐Gea, M. L., Lecumberri, R., Terleira‐Fernández, A. I., & Vargas, E. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12610 · Cited by 111
“1%, respectively) were much lower than rates of recurrent VTE and ACS reported in the dabigatran arm of the RE-MEDY study (21).”
BackgroundKlemen, N. D., Feingold, P. L., Hashimoto, B., Wang, M., Kleyman, S., Brackett, A. L., Gross, C. P., & Pei, K. Y. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30211-8 · Cited by 96
Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants
Geldhof, V., Vandenbriele, C., Verhamme, P. B., & Vanassche, T. (2014) · Thrombosis Journal · doi:10.1186/1477-9560-12-21 · Cited by 98
Hoffman, M., & Dickneite, G. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-05-0431 · Cited by 101
When Direct Oral Anticoagulants Should Not Be Standard Treatment
Bejjani, A., Khairani, C. D., Assi, A. A., Piazza, G., Sadeghipour, P., Talasaz, A. H., Fanikos, J. R., Connors, J. M., Siegal, D. M., Barnes, G. D., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.10.038 · Cited by 98
Self-citationPharmacogenetics of dabigatran etexilate interindividual variability
Dimatteo, C., D’Andrea, G., Vecchione, G., Paoletti, O., Cappucci, F., Tiscia, G. L., Buono, M., Grandone, E., Testa, S., & Margaglione, M. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.05.025 · Cited by 98
Artang, R., Rome, E., Nielsen, J. D., & Vidaillet, H. J., Jr. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.08.027 · Cited by 91
Goldhaber, S. Z., Eriksson, H., Kakkar, A., Schellong, S., Feuring, M., Fraessdorf, M., Kreuzer, J., Schueler, E., & Schulman, S. (2016) · Vascular Medicine · doi:10.1177/1358863x16668588 · Cited by 89
Self-citationde Winter, M. A., Buller, H. R., Carrier, M., Cohen, A. T., Hansen, J., Kaasjager, K. A. H., Kakkar, A. K., Middeldorp, S., Raskob, G. E., Sørensen, H. T., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac776 · Cited by 87
“EINSTEIN-CHOICE was a double-blind, randomized, controlled trial comparing two doses of rivaroxaban and aspirin.14 GARFIELD-VTE was a prospective, international observational registry for long-term follow-up of VTE.15 The Multiple Environmental and Genetic Assessment of Risk Factors for Venous Thrombosis (MEGA) follow…”
MethodInfluentialSelf-citationUpdate on the management of venous thromboembolism
Bartholomew, J. R. (2017) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.84.s3.04 · Cited by 91
“16 19 The risk of major bleeding, and in particular intracranial bleeding, has been shown to be less with DOACs compared with VKAs in 2 meta-analysis trials.”
BackgroundAnticoagulation for people with cancer and central venous catheters
Akl, E. A., Ramly, E. P., Kahale, L. A., Yosuico, V. E. D., Barba, M., Sperati, F., Cook, D., & Schünemann, H. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006468.pub5 · Cited by 89
Butler, J., Malan, E., Chunilal, S. D., Tran, H., & Hapgood, G. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-04-0301 · Cited by 83
“Dabigatran has also been demonstrated to be efficacious in the treatment of acute venous thrombosis and secondary prevention of recurrent venous thromboembolism (2, 3).”
BackgroundRaskob, G. E., Buller, H. R., Prins, M. H., Segers, A. E. M., Shi, M., Schwocho, L. R., van Kranen, R., & Mercuri, M. F. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12230 · Cited by 88
Anticoagulation for people with cancer and central venous catheters
Kahale, L. A., Tsolakian, I. G., Hakoum, M. B., Matar, C. F., Barba, M., Yosuico, V. E. D., Terrenato, I., Sperati, F., Schünemann, H. J., & Akl, E. A. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006468.pub6 · Cited by 85
Robertson, L., Kesteven, P. J., & McCaslin, J. E. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010956.pub2 · Cited by 86
Metadata
- Authors
- Schulman, S., Kearon, C., Kakkar, A. K., Schellong, S., Eriksson, H., Baanstra, D., Kvamme, A. M., Friedman, J., Mismetti, P., & Goldhaber, S. Z.
- Affiliations
- Karolinska University Hospital (SE)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Thrombosis Research Institute (GB)
- Krankenhaus Dresden-Friedrichstadt (DE)
- Sahlgrenska University Hospital (SE)
- Boehringer Ingelheim (Netherlands) (NL)
- Boehringer Ingelheim (Norway) (NO)
- Boehringer Ingelheim (United States) (US)
- Centre Hospitalier Universitaire de Saint-Étienne (FR)
- Brigham and Women's Hospital (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-02-21
- Volume
- 368
- Issue
- 8
- Pages
- 709-718
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2112378432
- Cited by
- 983
- References
- 25
- Citations by year
- 2026: 22 · 2025: 26 · 2024: 42 · 2023: 32 · 2022: 38 · 2021: 65 · 2020: 62 · 2019: 67 · 2018: 90 · 2017: 71 · 2016: 103 · 2015: 124 · 2014: 141 · 2013: 97
- FWCI
- 135.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- dabigatran, warfarin, venous thromboembolism, long-term anticoagulation, recurrent venous thromboembolism, major bleeding, acute coronary syndrome, direct oral anticoagulants, non-inferiority, thromboprophylaxis, thrombolysis, anticoagulant reversal
- MeSH terms
- Dabigatran, Adolescent, Adult, Aged, Aged, 80 and over, Benzimidazoles, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Recurrence, Risk, Warfarin, beta-Alanine, International Normalized Ratio, Venous Thromboembolism, Young Adult, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.